PME SYMPOSIA
PME Lunch Symposium (Non-CME)
A Treatment Option for Patients With HFrEF Following a Worsening HF Event
Sponsored by VeroScience
Circadian bromocriptine-QR therapy attenuates elevated sympathetic tone, postprandial dysmetabolism, and an immune proinflammatory state and reduces adverse cardiovascular event rate: Clinical studies summary in T2DM subjects
CHAIRED BY:
Michael Ezrokhi, PhD
Friday, May 19, 2023
11:00 AM – 12:00 PM
Ballroom: Sun B
Program Description:
The circadian peak of dopaminergic activity at the brain’s clock center is a critical modulator (via the neuroendocrine axis) of daily fuel metabolism, immunity, and vascular biology. An attenuation of this dopaminergic circadian peak activity stimulates the brain clock induction of metabolic syndrome and this adverse clock condition can be “locked in” by chronic exposure to western lifestyle factors (e.g., high fat diet, psychosocial stress, and altered sleep/wake architecture) – to drive chronic increases in sympathetic nervous system activity, the HPA axis, insulin resistance, and importantly, a strong systemic pro-oxidative/pro-inflammatory condition that in turn drives cardiometabolic disease. Circadian-timed bromocriptine-QR therapy, a quick release formulation of the dopamine D2 receptor agonist bromocriptine, to “reset” and reinstate the endogenous circadian peak of brain dopaminergic activity in T2DM subjects, attenuated this pathophysiological shift, reduced the proinflammatory state and in a large population study reduced major adverse cardiovascular events by 52% within 1 year.
About the Speaker:
Matthew J. Budoff, MD, FACC, FAHA is the Endowed Chair of Preventive Cardiology at the Lundquist Institute at Harbor-UCLA Medical Center and a Professor of Medicine at the David Geffen School of Medicine at UCLA. Dr. Budoff earned his MD from the George Washington University School of Medicine in Washington, DC. He completed both; his residency and his fellowship in cardiology at Harbor-UCLA Medical Center in Torrance, CA. Dr. Budoff is board certified in Cardiovascular Disease and Cardiovascular Computed Tomography. He is a Fellow of the American Heart Association, the American College of Cardiology, the Society of Cardiac Angiography and Intervention and the Society of Cardiovascular Computed Tomography. Dr. Budoff is a widely published researcher and international lecturer who holds several US patents. He sits on the Editorial Boards for the Journal of Invasive Cardiology, Clinical Cardiology, the International Journal of Cardiodiabetes and others.
PME Lunch Symposium (Non-CME)
A Treatment Option for Patients with Heart Failure
Sponsored by AstraZeneca
CHAIRED BY:
Victor N. Howard, MD, FACC
Saturday, May 20, 2023
11:00 AM – 12:00 PM
Ballroom: Sun B
Program Description:
- Understand the prevalence and burden of HF in the US, and the intersection of HF with Chronic Kidney Disease
- Describe the use of dapagliflozin (Farxiga) in patients with HFrEF, the results of the Landmark DAPA-HF trial
- Describe the use of dapagliflozin (Farxiga) in patients with CKD, the results of the DAPA-CKD trial, focusing on a consistent benefit in those patients with CKD with and without a history of heart failure.
- Describe strategies for implementation of dapagliflozin in clinical practice for the treatment of HFrEF
About the Speaker:
Matthew J. Budoff, MD, FACC, FAHA is the Endowed Chair of Preventive Cardiology at the Lundquist Institute at Harbor-UCLA Medical Center and a Professor of Medicine at the David Geffen School of Medicine at UCLA. Dr. Budoff earned his MD from the George Washington University School of Medicine in Washington, DC. He completed both; his residency and his fellowship in cardiology at Harbor-UCLA Medical Center in Torrance, CA. Dr. Budoff is board certified in Cardiovascular Disease and Cardiovascular Computed Tomography. He is a Fellow of the American Heart Association, the American College of Cardiology, the Society of Cardiac Angiography and Intervention and the Society of Cardiovascular Computed Tomography. Dr. Budoff is a widely published researcher and international lecturer who holds several US patents. He sits on the Editorial Boards for the Journal of Invasive Cardiology, Clinical Cardiology, the International Journal of Cardiodiabetes and others.
